SRNE - Sorrento reports publication of a series of SARS-CoV-2 MPro inhibitors for treatment COVID-19

Sorrento Therapeutics (NASDAQ:SRNE) announces the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors with potent activities for both MPro and cathepsin L, a key host enzyme for SARS-CoV-2 entry into host cells at Texas A&M University. Shares up 7.4% premarket at $5.31. SARS-CoV-2 main protease (MPro) is a key enzyme for the viral life cycle including virus entry, replication and packaging. In the publication, a representative analog of the series, MPI8, demonstrated dual inhibition of MPro and cathepsin L with high potency and selectivity (IC50 values for MPro and cathepsin L are 105 nM and 1.2 nM, respectively). A promising analog with features distinguished from current reported SARS-CoV-2 MPro inhibitors has been systematically evaluated and advanced to a late stage of pre-clinical phase. "The oral MPro inhibitor together with Sorrento’s other ongoing therapeutic intervention approaches reflect our efforts to create a ‘mutation-agnostic’ global anti-COVID strategy to combat COVID-19 variants of concern,

For further details see:

Sorrento reports publication of a series of SARS-CoV-2 MPro inhibitors for treatment COVID-19